News – Page 1089 – Endpoints News

Bain, RA back InflaRx’s $55M round after early study produces promising results

8 years ago

FDA experts offer a unanimous endorsement for Spark’s pioneering AAV gene therapy for blindness

8 years ago

NIH allies with 11 top cancer biopharma players in $215M drive to explore biomarkers, speed R&D

8 years ago

Amgen’s Bradway elected PhRMA chair; Abingworth provides £13M A round to antiviral startup VirionHealth

8 years ago

Karyopharm bags a $193M Asian deal for selinexor and followup drug, shares jump

8 years ago

Medicxi kickstarts a new cancer drug developer with $19M launch round

8 years ago

In a new setback, FDA kicks back AcelRx’s application for pain med — shares tank again

8 years ago

J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide

8 years ago

Positive PhIII can't salvage Merck's anacetrapib, now relegated to the scrap heap

8 years ago

Battered by mixed PhIII data, Trevena axes R&D staff and hunkers down around lead pain drug

8 years ago

Ardelyx steps up with a better round of PhIII data to compare with rivals at Ironwood, Synergy

8 years ago

Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study

8 years ago

The FDA's insider view on Aerie’s glaucoma drug: Yes on efficacy, but…

8 years ago

Ten big lobbying groups turn their guns on Allergan's controversial patent gambit

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

Former FDA chief von Eschenbach steps up his advisory role at Malin

8 years ago

With just a little encouragement, biotech investors are ready to fall in love again

8 years ago

Scott Gottlieb likes his job running the FDA, but he isn't ruling out a big HHS promotion

8 years ago

India’s Lupin bags Symbiomix and its newly approved antibiotic for $150M-plus

8 years ago

Deerfield commits $50M-plus to translational drug R&D at the Broad

8 years ago

Amgen catches a break as FDA rejects Neulasta knockoff; Zafgen gets a new CEO as Hughes moves to top science job

8 years ago

Giant Merck buddies up with little KalVista on lead drug, igniting stock with a $760M deal

8 years ago

AbbVie jumps on the oncolytics bandwagon, embracing Turnstone in new collaboration

8 years ago

Eli Lilly concedes a PhIII flop for abemaciclib as breakout strategy flounders

8 years ago

First page Previous page 1086 1087 108810891090 1091 1092 Next page Last page